Avantor Stock Valuation Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Yahoo Finance
- Price Discount Analysis: Avantor's current stock price is 32.1% below its intrinsic value estimate, indicating that despite a 71.4% decline over the past five years, the stock is still viewed as undervalued under the discounted cash flow model, potentially attracting institutional investor interest and boosting market confidence.
- Cash Flow Forecast: Based on the latest free cash flow of approximately $433.2 million, the discounted cash flow model suggests an intrinsic value of $15.21 per share, indicating that the current stock price is below this estimate, and if operational and margin improvements can be achieved, it may narrow the gap between price and intrinsic value.
- Sales Multiple Assessment: Avantor's price-to-sales ratio is about 1.1x, significantly lower than the life sciences industry average of 4.0x and the peer group average of 5.1x, reflecting that the market is pricing its sales at a discount relative to what the model implies for a company with its characteristics, indicating competitive weaknesses.
- Investor Confidence Consideration: Despite Avantor facing challenges with long-term weak returns, renewed interest from institutional investors may support its future cash flow and margin improvements; however, any setbacks in margin or cash flow efforts could quickly undermine the current undervaluation argument.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 10.200
Low
8.00
Averages
11.67
High
16.00
Current: 10.200
Low
8.00
Averages
11.67
High
16.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avantor Stock Valuation Analysis
- Price Discount Analysis: Avantor's current stock price is 32.1% below its intrinsic value estimate, indicating that despite a 71.4% decline over the past five years, the stock is still viewed as undervalued under the discounted cash flow model, potentially attracting institutional investor interest and boosting market confidence.
- Cash Flow Forecast: Based on the latest free cash flow of approximately $433.2 million, the discounted cash flow model suggests an intrinsic value of $15.21 per share, indicating that the current stock price is below this estimate, and if operational and margin improvements can be achieved, it may narrow the gap between price and intrinsic value.
- Sales Multiple Assessment: Avantor's price-to-sales ratio is about 1.1x, significantly lower than the life sciences industry average of 4.0x and the peer group average of 5.1x, reflecting that the market is pricing its sales at a discount relative to what the model implies for a company with its characteristics, indicating competitive weaknesses.
- Investor Confidence Consideration: Despite Avantor facing challenges with long-term weak returns, renewed interest from institutional investors may support its future cash flow and margin improvements; however, any setbacks in margin or cash flow efforts could quickly undermine the current undervaluation argument.
See More
Avantor to Release Q2 2026 Financial Results on July 29
- Earnings Release Schedule: Avantor will announce its Q2 2026 financial results before the market opens on July 29, providing investors with critical financial data and performance analysis to assess the company's operational status.
- Conference Call Timing: On the same day at 8:00 a.m. Eastern Daylight Time, Avantor will hold a conference call to discuss the earnings report, allowing investors to listen live via the investor section of the company's website, enhancing transparency and communication efficiency.
- Webcast Replay Availability: A replay of the webcast will be available for 30 days post-conference, ensuring that investors who could not participate live can access important information, further improving interaction between the company and its investors.
- Company Background: Avantor is a leading life sciences tools company dedicated to providing mission-critical products and services to the life sciences and advanced technology sectors, serving over 300,000 customer locations in 180 countries, showcasing its significant position and influence in the industry.
See More
Avantor Announces Q2 2026 Financial Results Release Schedule
- Earnings Release Schedule: Avantor will release its Q2 2026 financial results before the market opens on July 29, showcasing the company's ongoing performance in the life sciences and advanced technology sectors, which is expected to impact investor confidence.
- Conference Call Timing: A conference call will be held on the same day at 8:00 a.m. Eastern Daylight Time to discuss the financial results, aiming to enhance communication with investors and improve transparency and trust.
- Live Webcast Availability: The session will be available via live audio webcast on Avantor's website in the Investor section, facilitating real-time information access for global investors and enhancing interaction between the company and its stakeholders.
- Replay Service: A replay of the webcast will be available for 30 days, ensuring that investors who cannot attend live can still access key information, further improving the comprehensiveness and accessibility of the company's disclosures.
See More
Avantor Inc Stock Surpasses Analyst Target Price
- Stock Performance: Avantor Inc's shares recently traded at $9.69, surpassing the average analyst 12-month target price of $9.67, indicating increased market confidence that may attract more investor interest.
- Analyst Reaction: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target price; the current market response to Avantor may prompt analysts to reassess their targets to reflect improvements in the company's fundamentals.
- Target Price Distribution: Among the 15 analysts covered by Zacks, target prices range from $7.00 to $19.00, with a standard deviation of $3.154, highlighting varying market perspectives on Avantor's future performance, necessitating cautious evaluation by investors.
- Investor Decision-Making: As the stock price exceeds the target price, investors face a choice: to hold on for potentially higher targets or consider taking profits to avoid risks of overvaluation, which will influence future market dynamics.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aimed at enhancing the company's competitiveness in life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep quality and regulatory experience from the life sciences, medical technology, and healthcare industries, having led global product approvals and complex regulatory engagements at Getinge, ensuring compliance in international markets.
- Strategic Importance: Avantor's CEO Emmanuel Ligner emphasized that Porreca's expertise will be crucial for enhancing operational capabilities and delivering mission-critical solutions, further solidifying Avantor's position as a trusted partner in the scientific journey.
- Customer Value Proposition: Porreca stated that quality and regulatory excellence are not just requirements but key value propositions for customers, and he aims to strengthen quality systems through data-driven insights to help clients accelerate the delivery of life-changing breakthroughs.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor has announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aiming to enhance operational efficiency in the life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep expertise in quality and compliance from his previous role at Getinge, where he led global product approvals and complex regulatory engagements, ensuring the company's compliance and competitiveness in international markets.
- Strategic Importance: CEO Emmanuel Ligner emphasized that Porreca's expertise will be vital for enhancing quality systems and delivering mission-critical solutions globally, thereby increasing customer trust and market position.
- Customer Value Proposition: Porreca stated that excellence in quality and regulatory affairs is not just a requirement but a key value proposition for customers, and he aims to leverage data-driven insights to strengthen quality systems and accelerate the delivery of life-changing breakthroughs.
See More
Avantor Stock Valuation Analysis
- Price Discount Analysis: Avantor's current stock price is 32.1% below its intrinsic value estimate, indicating that despite a 71.4% decline over the past five years, the stock is still viewed as undervalued under the discounted cash flow model, potentially attracting institutional investor interest and boosting market confidence.
- Cash Flow Forecast: Based on the latest free cash flow of approximately $433.2 million, the discounted cash flow model suggests an intrinsic value of $15.21 per share, indicating that the current stock price is below this estimate, and if operational and margin improvements can be achieved, it may narrow the gap between price and intrinsic value.
- Sales Multiple Assessment: Avantor's price-to-sales ratio is about 1.1x, significantly lower than the life sciences industry average of 4.0x and the peer group average of 5.1x, reflecting that the market is pricing its sales at a discount relative to what the model implies for a company with its characteristics, indicating competitive weaknesses.
- Investor Confidence Consideration: Despite Avantor facing challenges with long-term weak returns, renewed interest from institutional investors may support its future cash flow and margin improvements; however, any setbacks in margin or cash flow efforts could quickly undermine the current undervaluation argument.
See More
Avantor to Release Q2 2026 Financial Results on July 29
- Earnings Release Schedule: Avantor will announce its Q2 2026 financial results before the market opens on July 29, providing investors with critical financial data and performance analysis to assess the company's operational status.
- Conference Call Timing: On the same day at 8:00 a.m. Eastern Daylight Time, Avantor will hold a conference call to discuss the earnings report, allowing investors to listen live via the investor section of the company's website, enhancing transparency and communication efficiency.
- Webcast Replay Availability: A replay of the webcast will be available for 30 days post-conference, ensuring that investors who could not participate live can access important information, further improving interaction between the company and its investors.
- Company Background: Avantor is a leading life sciences tools company dedicated to providing mission-critical products and services to the life sciences and advanced technology sectors, serving over 300,000 customer locations in 180 countries, showcasing its significant position and influence in the industry.
See More
Avantor Announces Q2 2026 Financial Results Release Schedule
- Earnings Release Schedule: Avantor will release its Q2 2026 financial results before the market opens on July 29, showcasing the company's ongoing performance in the life sciences and advanced technology sectors, which is expected to impact investor confidence.
- Conference Call Timing: A conference call will be held on the same day at 8:00 a.m. Eastern Daylight Time to discuss the financial results, aiming to enhance communication with investors and improve transparency and trust.
- Live Webcast Availability: The session will be available via live audio webcast on Avantor's website in the Investor section, facilitating real-time information access for global investors and enhancing interaction between the company and its stakeholders.
- Replay Service: A replay of the webcast will be available for 30 days, ensuring that investors who cannot attend live can still access key information, further improving the comprehensiveness and accessibility of the company's disclosures.
See More
Avantor Inc Stock Surpasses Analyst Target Price
- Stock Performance: Avantor Inc's shares recently traded at $9.69, surpassing the average analyst 12-month target price of $9.67, indicating increased market confidence that may attract more investor interest.
- Analyst Reaction: When a stock reaches its target price, analysts typically either downgrade their valuation or raise their target price; the current market response to Avantor may prompt analysts to reassess their targets to reflect improvements in the company's fundamentals.
- Target Price Distribution: Among the 15 analysts covered by Zacks, target prices range from $7.00 to $19.00, with a standard deviation of $3.154, highlighting varying market perspectives on Avantor's future performance, necessitating cautious evaluation by investors.
- Investor Decision-Making: As the stock price exceeds the target price, investors face a choice: to hold on for potentially higher targets or consider taking profits to avoid risks of overvaluation, which will influence future market dynamics.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aimed at enhancing the company's competitiveness in life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep quality and regulatory experience from the life sciences, medical technology, and healthcare industries, having led global product approvals and complex regulatory engagements at Getinge, ensuring compliance in international markets.
- Strategic Importance: Avantor's CEO Emmanuel Ligner emphasized that Porreca's expertise will be crucial for enhancing operational capabilities and delivering mission-critical solutions, further solidifying Avantor's position as a trusted partner in the scientific journey.
- Customer Value Proposition: Porreca stated that quality and regulatory excellence are not just requirements but key value propositions for customers, and he aims to strengthen quality systems through data-driven insights to help clients accelerate the delivery of life-changing breakthroughs.
See More
Avantor Appoints New Executive VP of Quality and Regulatory
- Executive Appointment: Avantor has announced the appointment of Gerard Porreca as Executive Vice President of Quality and Regulatory, responsible for global quality assurance, quality systems, and regulatory affairs, aiming to enhance operational efficiency in the life sciences and advanced technology sectors.
- Extensive Experience: Porreca brings deep expertise in quality and compliance from his previous role at Getinge, where he led global product approvals and complex regulatory engagements, ensuring the company's compliance and competitiveness in international markets.
- Strategic Importance: CEO Emmanuel Ligner emphasized that Porreca's expertise will be vital for enhancing quality systems and delivering mission-critical solutions globally, thereby increasing customer trust and market position.
- Customer Value Proposition: Porreca stated that excellence in quality and regulatory affairs is not just a requirement but a key value proposition for customers, and he aims to leverage data-driven insights to strengthen quality systems and accelerate the delivery of life-changing breakthroughs.
See More
